Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Link Between Serotonin and Depression is a Myth, Says Psychiatrist

By Drug Discovery Trends Editor | April 22, 2015

The widely held belief that depression is caused by low levels of serotonin and that certain antidepressants raise the levels of this neurotransmitter, is a myth, according to a psychiatrist in an editorial article in The BMJ this week.

In fact, David Healy, a professor of psychiatry at Bangor University in Wales and author of Let Them Eat Prozac: The Unhealthy Relationship Between the Pharmaceutical Industry and Depression, contends that psychiatrists still don’t have a clear understanding of how selective serotonin reuptake inhibitors (SSRIs) precisely work. SSRIs are a class of several drugs for mood disorder — they include citalopram (Celexa), fluoxetine (Prozac) and sertraline (Zoloft).

Healy writes that the link between low levels of serotonin and depression has been “the marketing of a myth” perpetuated by pharmaceutical companies after the 1980s, when concerns emerged about tranquilizer dependence.

“Drug companies marketed SSRIs for depression,” writes Healy, “even though they were weaker than older tricyclic antidepressants, and sold the idea that depression was the deeper illness behind the superficial manifestations of anxiety.” Healy describes the approach as an “astonishing success, central to which was the notion that SSRIs restored serotonin levels to normal, a notion that later transmuted into the idea that they remedied a chemical imbalance.”

Despite the idea that SSRIs restore abnormal serotonin levels in the brain isn’t substantiated by evidence, this thinking persists because it was adopted by physicians as a simple way to communicate the disorder and its treatment to patients, according to Healy. And that led to what he calls a “costly distraction,” where meanwhile, “more effective and less costly treatments were marginalized.

“The success of the SSRIs pushed older tricyclic antidepressants out of the market.”

That said, Healy stresses that serotonin “is not irrelevant.” But, he says, that the marketing history of SSRIs raises questions about whether “a plausible but mythical account of biology and treatment” has allowed physicians to “put aside clinical trial data that show no evidence of lives saved or restored function.”

More than 30 million Americans — one in 10 Americans — take an antidepressant medication.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE